References
- DeSanty KP, Amabile CM. Antidepressant-induced liver injury. Ann Pharmacother. 2007; 41(7): 1201–1211.
- Navarro VJ, Senior JR. Drug-related hepatotoxicity. N EngI J Med. 2006; 354(7): 731–739.
- Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990; 11(2): 272–276.
- Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol. 2005; 33(1): 155–164.
- Food and Drug Administration. Hy's law and current practice: a hypothesis in use. http://www.fda.gov/cder/livertox/Presentations/im1389/sldOl3.htm. Accessed July 17, 2007.
- Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006; 296(1): 87–93.
- Rosenzweig P, Miget N, Brohier S. Transaminase elevation on placebo during phase I trials: prevalence and significance. Br J Clin Pharmacol. 1999; 48(1): 19–23.
- Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003; 98(5): 960–967.
- Wernicke J, Pangallo B, Wang F, Murray I, Henck J, Knadler MP, D'Souza DN, Uetrecht JP. Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Current Drug Safety. 2008; 3: 132–142.
- Wernicke J, Acharya N, Strombom I, Gahimer JL, D'Souza DN, Di Pietro N, Uetrecht JP. Hepatic effects of duloxetine—II: spontaneous reports and epidemiology of hepatic events. Current Drug Safety. 2008; 3: 143–153.
- Liguori MJ, Waring JF. Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions. Expert Opin Drug Metab Toxicol. 2006; 2(6): 835–846.
- Hanje AJ, Pell LJ, Votolato NA, Frankel WL, Kirkpatrick RB. Case report: fulminant hepatic failure involving duloxetine hydrochloride. Clin Gastroenterol Hepatol. 2006; 4(7): 912–917.
- Duh MS, Walker AM, Kronlund KH Jr. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts. Pharmacoepidemiol Drug Saf. 1999; 8(4): 275–283.
- Sgro C, Clinard F, Ouazir K. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002; 36(2): 451–455.
- de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004; 58(1): 71–80.
- Ibanez L, Perez E, Vidal X, Laporte JR; Grup d'Estudi Multicèntric d'Hepatotoxicitat Aguda de Barcelona (GEMHAB). Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol. 2002; 37(5): 592–600.
- Strombom I, Wernicke J, Acharya N, D'Souza DN, Beyrer JK. Hepatic effects of duloxetine—III: Analysis of Hepatic Events Using External Data Sources. Current Drug Safety. 2008; 3: 154–162.
- Cardona X, Avila A, Castellanos P. Venlafaxine-associated hepatitis. Ann Intern Med. 2000; 132(5): 417.
- Horsmans Y, De CM, Sempoux C. Venlafaxine-associated hepatitis. Ann Intern Med. 1999; 130(11): 944.
- Phillips BB, Digmann RR, Beck MG. Hepatitis associated with low-dose venlafaxine for postmenopausal vasomotor symptoms. Ann Pharmacother. 2006; 40(2): 323–327.
- Sencan I, Sahin I, Ozcetin A. Low-dose venlafaxine-associated liver toxicity in chronic hepatitis. Ann Pharmacother. 2004; 38(2): 352–353.
- Shaw MW, Sheard JD. Fatal venlafaxine overdose with acinar zone 3 liver cell necrosis. Am J Forensic Med Pathol. 2005; 26(4): 367–368.
- Spigset O, Hägg S, Bate A. Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int Clin Psychopharmacol. 2003; 18(3): 157–161.
- Gahimer J, Wernicke J, Yalcin I, Ossana MJ, Wulster-Radcliffe M, Viktrup L. A retrospective pooled analysis of duloxetine safety in 23983 subjects. Cur Med Res Op. 2007; 23(1): 175–184.